SCHEMBL986079

SCHEMBL986079

COc1ccc(C#CC[C@@H](O)c2ccccc2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.43
GAA P10253 3/20 0.40
AOC3 Q16853 2/20 0.38
PBRM1 Q86U86 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTR1A P08908 1/20 0.38
CYP2D6 P10635 2/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
NOS2 P35228 2/20 0.37
FAAH O00519 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
SLC5A2 P31639 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12923937 0.83 HTT (0.47) AOC3KDM4ESMN1; SMN2TDP1SLC6A2
SCHEMBL28864433 0.79 MMP2 (0.50) GAAAOC3PBRM1KDM4ESMN1; SMN2
SCHEMBL988229 0.78 CYP2D6 (0.38) ACACBGAAAOC3PBRM1CYP2D6
SCHEMBL988231 0.78 CYP2D6 (0.38) ACACBGAAAOC3PBRM1CYP2D6
SCHEMBL12949390 0.73 MEN1 (0.44) GAAAOC3KDM4ESMN1; SMN2TDP1
SCHEMBL5014307 0.68 KMT2A (0.60) AOC3KDM4EL3MBTL1KMT2A
SCHEMBL10191871 0.68 ACACB (0.46) ACACBGAAKDM4ETDP1
SCHEMBL28864450 0.68 KMT2A (0.53) AOC3KDM4EL3MBTL1KMT2AMEN1
SCHEMBL94698 0.66 LMNA (0.54) GAAAOC3KDM4ECYP2D6L3MBTL1
SCHEMBL30556452 0.66 GAA (0.52) ACACBGAAAOC3TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003776-A1 TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003776-A1 TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF TPMT, TYMS, QDPR ACACB 2554/4885GAA 859/4885AOC3 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.